Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension Study of Semapimod in Crohn's Disease
NCT00741910Phase 2Completed
- Sponsor
- Ferring Pharmaceuticals
- Start
- Jul 2003
- Primary completion
- Jun 2006
- Modality
- Classical Binding Small Molecules
- Countries
- 4
01
Overview
Phase 2, open-label, single-arm trial of semapimod in Crohn's disease, sponsored by Ferring Pharmaceuticals. Primary endpoint: Crohn's Disease Activity Index. Started Jul 2003; status: completed.
02
Drugs
semapimod
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT00741910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00741910.